Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Leading industry insight at your fingertips

Video, audio, and proprietary data sets br ing our articles and analyses to life.

Numerous search filters allow for precise content targeting, and articles and searches can be saved and shared with one-click

Set custom email alerts on any topic or search criteria so you never miss what you need to know most.




Phone (US): +1 212-520-2765
Phone (UK & Europe): +44 (0) 20 7017-4191

Subscribe today and get access to:

  • Real time news, analysis and opinion on regulation and reimbursement policy, legislation and compliance and the implications to the market.
  • Exclusive in-depth interviews with the key decision-makers in the global generics, biosimilars and value-added medicines industries
  • Detailed analyses of company strategies, pipelines and prospects
  • Pipeline Watch: Opportunities arising from key intellectual-property events around the world, powered by IQVIA’s Ark patent-intelligence database
  • Price Watch: Up-to-date pricing information and trends for the UK pharmacy market, based on exclusive data supplied by market researcher WaveData
  • Create email alerts tailored to your needs and refine using faceted search.
  • My View, a custom home page that follows your topics of interest.
  • Scan headlines to be up on the latest, and tailor the service to your specific needs with refined targeted searches, and custom email alerts and RSS feeds so you never miss a development.
  • “Ask the Analyst” exclusive client service to find out more about topics, developments, or trends to support presentations, proposals, or business critical decisions where your credibility is on the line.